Risk Assessment of Thromboembolic Disease In Patients Treated For Multiple Myeloma

被引：0
|
作者：
Douma, Soukaina [1 ]
Naim, Sara [1 ]
Benmoussa, Amine [1 ]
Berrada, Sophia [1 ]
Lamchahab, Mouna [1 ]
Khoubila, Nissrine [1 ]
Rachid, Mohammed [1 ]
Qachouh, Meryem [1 ]
Cherkaoui, Siham [1 ]
Madani, Abdellah [1 ]
机构：
[1] Univ Hosp, Ctr IBN ROCHD, Casablanca, Morocco
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-556
引用
收藏
页码：S570 / S570
页数：1
相关论文
共 50 条
  • [21] Multiple myeloma: disease response assessment
    Zamagni, E.
    Tacchetti, P.
    Terragna, C.
    Cavo, M.
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (09) : 831 - 837
  • [22] A shortened activated partial thromboplastin time predicts thromboembolic risk in patients with newly diagnosed multiple myeloma
    Carter, A.
    Rossini, F.
    Borella, C.
    Coccini, V
    Cammarota, S.
    Rossi, F.
    Poghani, E. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 136 - 136
  • [23] Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
    Hussein, Mohamad A.
    THROMBOSIS AND HAEMOSTASIS, 2006, 95 (06) : 924 - 930
  • [24] Bleeding risk in patients with multiple myeloma treated for venous thromboembolism: a MarketScan analysis
    Adrianzen-Herrera, Diego
    Lutsey, Pamela L.
    Giorgio, Katherine
    Walker, Robert F.
    Zakai, Neil A.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (01)
  • [25] Assessment and management of infectious risk in multiple sclerosis patients treated with disease-modifying therapies
    Zingaropoli, Maria Antonella
    Pasculli, Patrizia
    Iannetta, Marco
    Perri, Valentina
    Tartaglia, Matteo
    Crisafulli, Sebastiano Giuseppe
    Merluzzo, Chiara
    Baione, Viola
    Mazzocchi, Lorenzo
    Taglietti, Ambra
    Pauri, Flavia
    Frontoni, Marco
    Altieri, Marta
    Gaeta, Aurelia
    Antonelli, Guido
    Conte, Antonella
    Mastroianni, Claudio
    Ciardi, Maria Rosa
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [26] Outcome assessment and risk assessment for hospital associated thromboembolic disease
    Morris, A. M.
    Speers, H.
    Lavery, R.
    Benson, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 10 - 10
  • [27] Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor
    le Seve, Julien Denis
    Guedon, Alexis F.
    Bordenave, Stephanie
    Agard, Christian
    Connault, Jerome
    Pistorius, Marc-Antoine
    Quereux, Gaelle
    Espitia, Olivier
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (11) : 1049 - 1056
  • [28] EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.
    Gul, Zartash
    Khan, Hasan
    Bashir, Qaiser
    Shah, Nina
    Parmar, Simrit
    Dinh, Yvonne T.
    Hosing, Chitra M.
    Popat, Uday R.
    Kebriaei, Partow
    Anderlini, Paolo
    Shpall, Elizabeth J.
    Giralt, Sergio
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD, 2012, 120 (21)
  • [29] Insights into the Assessment of Measurable Residual Disease (MRD) in Patients With Multiple Myeloma
    Costa, Luciano J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 11 - 16
  • [30] Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
    Maiolino, Angelo
    Da Costa, Elaine Sobral
    Orfao, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 13
12345